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The prodrug nifurtimox has been used formore than 40 years
to treat Chagas disease and forms part of a recently approved
combinational therapy that targets West African trypanosomi-
asis.Despite this, itsmodeof action is poorly understood.Detec-
tion of reactive oxygen and nitrogen intermediates in nifurti-
mox-treated extracts led to the proposal that this drug induces
oxidative stress in the target cell. Here, we outline an alternative
mechanism involving reductive activation by a eukaryotic type I
nitroreductase. Several enzymes proposed to metabolize nifur-
timox, including prostaglandin F2 synthase and cytochrome
P450 reductase, were overexpressed in bloodstream-formTryp-
anosoma brucei. Only cells with elevated levels of the nitrore-
ductase displayed altered susceptibility to this nitrofuran,
implying a key role in drug action. Reduction of nifurtimox by
this enzyme was shown to be insensitive to oxygen and yields
a product characterized by LC/MS as an unsaturated open-
chain nitrile. This metabolite was shown to inhibit both par-
asite and mammalian cell growth at equivalent concentra-
tions, in marked contrast to the parental prodrug. These
experiments indicate that the basis for the selectivity of nifur-
timox against T. brucei lies in the expression of a parasite-
encoded type I nitroreductase.
Across the tropics, 10 million people are infected by the par-
asites Trypanosoma cruzi and Trypanosoma brucei, the causa-
tive agents of Chagas disease and human African trypanosomi-
asis, respectively (1, 2). They are responsible for 60,000 deaths
per year and represent amajor public health problem in regions
of the world least able to deal with the associated economic
burden. Their primary route of transmission is by blood-suck-
ing insect vectors. However, other pathways, notably blood
transfusion, organ transplantation, and illicit drug usage cou-
pled with population migration, have resulted in both infec-
tions becoming problematic in non-endemic areas (3–5). Cha-
gas disease is an emerging problem with as many as 300,000
people in the United States infected by T. cruzi, and blood sup-
plies are now routinely screened for the parasite. Current treat-
ment of both infections is restricted to a series of drugs whose
mode(s) of action are poorly understood (6). Establishing how
existing therapies work could contribute to more effective
treatment and aid drug development.
The five-nitrofuran drug nifurtimox has been used for more
than 40 years to treat Chagas disease. Its use is controversial as
it is toxic, reportedly carcinogenic, and of limited efficacy.
Additionally, T. cruzi strains refractory to treatment have been
isolated, a situation compounded by failure to complete the
recommended drug schedules. Nifurtimox drug regimes can
take up to 4months and are frequently associatedwith unpleas-
ant side effects. Despite these problems, nifurtimox, as part of
the nifurtimox-eflornithine combination therapy, is now rec-
ommended for late-stage West African sleeping sickness (7, 8)
and is also undergoing assessment as a treatment for pediatric
neuroblastoma (9, 10).
As with most nitroheterocyclic agents, nifurtimox functions
as a prodrug and must undergo activation by nitroreduction.
Two classes of enzyme can catalyze this process, the type I and
type II nitroreductases (11). Type I nitroreductases are
NAD(P)H-dependent, FMNbinding proteins commonly found
in bacteria but rare in eukaryotes. They mediate a two-electron
reduction of the nitro group to generate a nitroso intermediate
(Reaction 1) that rapidly undergoes reduction to a hydroxyla-
mine derivative (Reaction 2):
RNO2  2e
 3 RNO
RNO  2e 3 RNHOH
REACTIONS 1 AND 2
For nitrofuran compounds, the hydroxylamine can then be
processed further to generate either the amine, which is
believed to be inert, or nitrenium cations that promote DNA
breakage (12–14). Alternatively, fragmentation of the furan
ring may occur, yielding open-chain nitriles (11, 15, 16).
Because reduction by type I nitroreductase does not involve
oxygen and does not result in the production of reactive oxygen
species, this activity is said to be “oxygen-insensitive.”
In contrast, the ubiquitous type II nitroreductases contain
FMN or FAD as a co-factor, and their activity is “oxygen-sensi-
tive.” They catalyze the one-electron reduction of a substrate,
forming a nitro anion radical (Reaction 3) (17). In the presence
of oxygen, this radical undergoes futile cycling, resulting in the
production of superoxide anions and regeneration of the parent
nitro-compound (Reaction 4) (18).
RNO2 e
 3 RNO2

RNO2
  O23 RNO2 O2

REACTIONS 3 AND 4
Following observations that nifurtimox-treated trypano-
somal extracts generated superoxide anions and nitro anion
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radicals, it was proposed that this compoundmediated its activ-
ity through induction of oxidative stress in reactions catalyzed
by type II nitroreductases (19–21). Several flavoproteins,
including dihydrolipoamide dehydrogenase, cytochrome P450
reductase, and trypanothione reductase, were subsequently
shown to mediate the one-electron reduction of nifurtimox in
vitro (21–23). To date there is insufficient functional evidence
to suggest that this occurs in vivo and that trypanosomes over-
expressing trypanothione reductase display the same suscepti-
bility to nifurtimox as control cells (24). The only experimental
evidence for superoxide anion involvement in nifurtimox tox-
icity is indirect and comes from studies on the trypanosomal
superoxide dismutase repertoire. T. brucei TbSODB1 null mu-
tants displayed enhanced sensitivity to nifurtimox (25). The
same pattern of redox cycling seen in T. cruzi is observed in
mammalian cells, and the selectivity of this prodrug toward the
parasite is not explained by this model. Despite these issues,
oxidative stress resulting from type II nitroreductase activity
has been generally accepted as the main trypanocidal mecha-
nism of nitrofurtimox, although this has been questioned
(26–28).
Recently, an alternative activation mechanism has been
proposed following the identification of two trypanosomal
enzymes that can catalyze the two-electron reduction of nifur-
timox (27, 29). One, a prostaglandin F2 synthase, also known
as theOldYellowEnzyme, expressed byT. cruzi, can reduce the
nitrofuran in vitro, but oxidoreductase activity only occurs
under anaerobic conditions. The contribution, if any, that this
enzyme makes to drug metabolism within the parasite has not
been established. The second pathway involves a trypanosomal
type I nitroreductase (NTR)2 that displays characteristics
shown by many of its bacterial homologues; the activity is oxy-
gen-insensitive, the enzyme contains FMN as co-factor, and it
can metabolize a wide range of nitro- and quinone-based com-
pounds. Using T. cruzi and T. brucei lines with altered levels of
this enzyme, a clear link between this nitroreductase activity
and nifurtimox activation has been demonstrated (27). Null
mutant/heterozygous cells display resistance to various nitro-
heterocyclic agents, including nifurtimox, whereas overexpres-
sion confers hypersensitivity. Additionally, T. cruzi selected for
resistance to nifurtimoxwere found to have lost one copy of the
chromosome containing the TcNTR gene.
The aim of this work was to determine the role of trypano-
somal NTRs in nifurtimox action. We show that although low
levels of oxygen consumption can be detected during nifurti-
mox reduction, the trypanosomal NTRs are predominantly
oxygen-insensitive enzymes that catalyze the four-electron
reduction of the nitrofuran under both aerobic and anaerobic
conditions. This produces an unsaturated open-chain nitrile
that displays equivalent cytotoxicity toward mammalian and
parasite cells, unlike the parental prodrug.
EXPERIMENTAL PROCEDURES
Cell Culturing—T. brucei (Lister 427, clone 221a and a deriv-
ative (2T1) engineered to constitutively express the tetracycline
repressor protein) bloodstream-form parasites were grown in
HMI-11 medium (30, 31). The 2T1 line was grown in the pres-
ence of 1 g ml1 of phleomycin. Transformed 2T1 parasite
lines overexpressing TbNTR, TbPGS, TbCPR-2, or TbCPR-3
were maintained in this medium supplemented with 2.5 g
ml1 of hygromycin.
A human acute monocytic leukemia cell line (THP-1) was
grown at 37 °C under a 5% CO2 atmosphere in RPMI 1640
medium supplemented with 10% fetal calf serum, 20 mM
HEPES (pH 8.0), 2 mM sodium glutamate, 2 mM sodium pyru-
vate, 2.5 units ml1 penicillin, and 2.5 g ml1 streptomycin.
Enzyme Activity—Recombinant TcNTR and TbNTR were
purified as described (27, 32). Type I nitroreductase activity was
measured spectrophotometrically by following nifurtimox
reduction (  435 nm,   18,000 M1 cm1). A standard
reaction mixture (1 ml) containing 50 mM Tris-Cl (pH 7.5),
NADH (100 M), and nifurtimox (100 M) was incubated at
room temperature for 5min. The background rate of nitrofuran
reduction was determined, and the reaction was initiated by
addition of trypanosomal enzyme (20 g). Type I nitroreduc-
tase activity was expressed as micromoles of nifurtimox
reduced min1 mg1 protein. For hypoxic conditions, all
reagents were preincubated in an anaerobic glove box (Belle
Technology Ltd, Weymouth, UK) under a 100% nitrogen (oxy-
gen-free) atmosphere for at least 1 h. Assays were performed in
sealed cuvettes, and reactions were initiated by injection of the
parasite enzyme in the reaction mix. Data were evaluated by
non-linear regression analysis using GraphPad Prism 5
(GraphPad Software, La Jolla, CA).
Oxygen Consumption Assay—Oxygen consumption was fol-
lowed using the Oxygen Biosensor System (BD Biosciences)
(33). A standard 200-l assay containing 50 mM Tris-Cl (pH
7.5) and nifurtimox (100 M) was equilibrated at 27 °C for 15
min in the presence of TcNTR, TbNTR (both 4 g), or cyto-
chrome P450/cytochrome P450 reductase-enriched micro-
somal fractions (0.1 g) (Sigma-Aldrich). Reactions were initi-
ated by addition of prewarmed NAD(P)H (100 M). Glucose
dehydrogenase (1 unit ml1) and glucose (3mM) were included
in the initial mixture to maintain the levels of the reduced elec-
tron donor. The change in fluorescence (excitation 486 nm,
emission  620 nm) was monitored.
LC/MS Analysis of Nifurtimox Metabolites—In a trypano-
somal type I nitroreductase-mediated reaction, nifurtimox (100
M) was completely reduced, and the residual enzyme was
removed by binding to nickel-nitrilotriacetic acid followed by
centrifugation. Supernatants were analyzed using a Series 1100
LC with SL Ion Trap MS (Agilent, Wokingham, UK). Separa-
tion was carried out on a Hypurity Elite 5-m C18 column (15
mm  2.1 mm) (Thermo Scientific, Hemel Hempstead, UK),
eluting with a 10–30% acetonitrile gradient at a flow rate of 0.2
ml min1. Metabolites were detected using a diode array (
at 250, 300, 340, and 450 nm), and theirm/z values were deter-
mined by positive electrospray ionization. MS was carried out
with a drying gas temperature of 325 °C, drying gas flow of 10
2 The abbreviations used are: NTR, trypanosomal type I nitroreductase; ESI,
electrospray ionization; TbCPR2 and TbCPR3, Trypanosoma brucei cyto-
chrome P450 reductase 2 and 3, respectively; TbNTR, Trypanosoma brucei
type I nitroreductase; TbPGS, Trypanosoma brucei prostaglandin F2 syn-
thase; TcNTR, Trypanosoma cruzi type I nitroreductase.
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liters min1, nebulizer gas pressure of 25 p.s.i., and capillary
voltage of 3500 V in full scanmode in them/z range of 50–400.
Positive and negative tandem MS was performed in automatic
mode using SmartFrag for ion fragmentation. Preparative
HPLC of the unsaturated open-chain nitrile was performed on
a Kromasil C18 column using a 10–30% acetonitrile gradient
with a flow rate of 2mlmin1. The peak fraction, as detected by
absorbance at 340 nm, was collected, and the solvent was
removed under vacuum. The product was resuspended in
dimethyl sulfoxide, and its purity was confirmed by mass spec-
troscopy and absorbance spectrum.
Antiproliferative Assays—T. brucei bloodstream-form para-
sites (1 103 ml1) or THP-1 cells (1 104 ml1) were seeded
in 200 l of growth medium containing different concentra-
tions of nifurtimox or unsaturated open-chain nitrile. After
incubation at 37 °C for 3 days (T. brucei) or 6 days (THP-1),
Alamar Blue (20 l) (Invitrogen) was added to each well, and
the plates were incubated for a further 8–16 h. Cell densities
were determined by monitoring the fluorescence of each cul-
ture using a Gemini fluorescent plate reader (Molecular
Devices (UK) Ltd, Wokingham, UK) at an excitation wave-
length of 530 nm, an emissionwavelength of 585 nm, and a filter
cutoff at 550 nm, and the drug concentration that inhibits cell
growth by 50% (IC50) was established.
RESULTS
Nifurtimox Activation in Trypanosomes Is Dependent on
Type I Nitroreductases—Several trypanosomal enzymes have
been implicated in the metabolism of nifurtimox, including
prostaglandin F2 synthase, cytochrome P450 reductase, and
NTR (27, 29, 34). To date, only NTR has been demonstrated to
activate this nitrofuran prodrug in vivo. Trypanosomes with
reduced NTR levels show resistance to nifurtimox, whereas
cells overexpressing the enzyme are hypersensitive (27). To
assess whether the other enzymes can metabolize nifurtimox,
the T. brucei genes encoding for prostaglandin F2 synthase
(TbPGS, AB034727) and two cytochrome P450 reductases
(TbCPR2, XM_822460 and TbCPR3, XM_823737) (numbering
in accordance with Portal et al. (34)) were cloned in-frame with
the 9e10 epitope from the human c-myc protein in a vector that
facilitated tetracycline-inducible gene expression (31). The
constructs were used to transform bloodstream-form T. brucei
generating the inducible overexpression lines designated
TbPGSex, TbCPR2ex, and TbCPR3ex. To demonstrate that pro-
tein expression was occurring, extracts were produced from
parasites grown in the presence of tetracycline and used in
Western blot analyses with a monoclonal antibody raised
against the 9e10 epitope. In all cases, a band of the size corre-
sponding to the recombinant protein was detected (Fig. 1A).
T. brucei bloodstream-form lines overexpressing TbPGS,
TbCPR2, or TbCPR3 were then treated with nifurtimox. Para-
sites with elevated levels of TbNTR were examined in parallel.
Only cellswith elevated levels ofTbNTRdisplayed an enhanced
susceptibility to the nitrofuran (Fig. 1B).
Metabolism of Nifurtimox by Trypanosomal Type I Nitro-
reductases—TcNTR and TbNTR have all the characteristics of
classic oxygen-insensitive type I nitroreductases and are able to
reduce a wide range nitroheterocyclic compounds in the pres-
ence of oxygen (27, 32, 35). However, in contrast to other sub-
strates, such as benznidazole and 2,6-dichlorophenolindophe-
nol, the interaction between nifurtimox and both trypanosomal
enzymes does not occur via classic ping-pong kinetics (Fig. 2,A
and B). To study the interaction of TbNTR or TcNTR toward
nifurtimox, assays were performed in the presence of a fixed
amount of parasite enzyme (20 g) using three concentrations
of NADH (60, 80, and 100 M) against various concentrations
of the prodrug (0–100M). Double reciprocal plots were linear
between 20 to 100 M nifurtimox for all three NADH concen-
trations (data shown is for TbNTR, with similar results
obtained forTcNTR) (Fig. 2B). However, the plots converged to
suggest that the interaction of NADH, nifurtimox, and the
trypanosomal enzymes is complex, possibly occurring through
more than one mechanism. As oxygen consumption and pro-
duction of reactive oxygen species is often associated with
nifurtimox metabolism (19–21, 36), we analyzed whether oxy-
gen levels had any effect on the enzyme activity. In three inde-
pendent experiments performed under hypoxic conditions, the
maximum nitroreductase activity was consistently higher than
in aerobic assays performed in parallel, irrespective of the
nitroreductase source (TcNTR or TbNTR) (Fig. 2C).
To determine whether oxygen was consumed during aerobic
nifurtimox reduction, the Oxygen Biosensor System, a fluores-
cence-based assay using a ruthenium-based fluorophore was
employed (33, 37). In this system, oxygen quenches fluores-
cence, and an increase in signal intensity denotes a decline in
oxygen levels. A series of control reactions validating this sys-
tem are shown in supplemental Fig. S1. In the presence of
FIGURE 1.Overexpressionof the trypanosomal type I nitroreductase, but
not other enzymes, enhances susceptibility of bloodstream-form T. bru-
cei to nifurtimox. A, Western blot analyses containing extracts (10 g) from
uninduced (-) and tetracycline-induced () T. brucei bloodstream-form cul-
tures expressing TbNTR, TbPGS, TbCPR2, or TbCPR3 were probed with an
anti-9E10 antibody. Loading was judged by Coomassie staining. B, dose
response of parental bloodstream-form parasites (F) and cells expressing
TbPGSex (), TbCPR2ex (Œ), TbCPR3ex (), or TbNTRex (f) to nifurtimox (NFX).
All curves are means from experiments performed in quadruplicate. The
insert contains IC50 values  S.D. The differences in susceptibility between
NTR-expressing cells and all other lines was statistically significant (p 0.01),
as assessed by Student’s t test.
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NADPH and microsomes enriched for human cytochrome
P450/cytochromeP450 reductase, reduction of nifurtimox via a
type II nitroreductase activity resulted in a time-dependent
increase in fluorescence, indicating that oxygen was being con-
sumed, and this activity was maintained throughout the dura-
tion (80 min) of the assay (Fig. 2D, curve a). By measuring the
initial rate of change in fluorescence in the presence of various
nifurtimox concentrations (supplemental Fig. S1), a specific
activity value was calculated: 33.3 4.5 of normalized fluores-
cence units min1 g protein1 for the microsomal extract.
When using TbNTR or TcNTR with NADH as electron donor,
nifurtimox reduction generated an increase in fluorescence
(Fig. 2D, curve b) but at a lower rate than that seen with micro-
somal preparations. Again, the rate of change in fluorescence
was dependent on nifurtimox levels, yielding a specific activity
value (0.7  0.5 of normalized fluorescence units min1 g
protein1) 50-fold lower than microsomal reactions. In con-
trast to assays using microsomal fractions enriched for human
cytochrome P450/cytochrome P450 reductase, the TcNTR- or
TbNTR-mediated oxygen consumption activity stopped after
30min because of removal of nifurtimox from the reaction. In
the presence of excessNADH, the oxygen consumption activity
resumed when more nifurtimox was added to the assay (sup-
plemental Fig. S1). Thus, although oxygen consumption does
occur during trypanosomal NTR-mediated nifurtimox reduc-
tion, the associated futile cycling appears to be limited, with
most nifurtimox undergoing reduction to form an unknown
product.
TheMajor Product ofNifurtimoxReduction Is anOpen-chain
Nitrile—The activity of type I nitroreductases can lead to the
formation of various products (Fig. 3). To identify which
metabolites are generated from nifurtimox, this nitrofuran was
enzymatically reduced by TcNTR or TbNTR under both aero-
bic and anaerobic conditions. In all cases, LC/MS analysis of the
resultant products yielded a single analyte (Fig. 4A) whosemass
spectrum contained parent molecular ions for [MH] and
[MNa] at 256 and 278, respectively (Fig. 4B). For compari-
son, in parallel experiments, nifurtimox eluted off the same
column at 33.5 min, and the mass spectrum contained a parent
molecular ion for [MH] at 288. Examination of the absorb-
ance spectrum of the reduction product gave a characteristic
profile reminiscent of the nifurtimox-derived metabolite gen-
erated by radiolysis (Fig. 4C) (38). On the basis of its size and
absorbance spectrum, the product was tentatively identified as
an unsaturated open-chain nitrile that results from the dehy-
dration of the furyl hydroxylamine and subsequent furan ring
opening. Further reduction of this end product to its saturated
form by TcNTR was observed, but this reaction occurred at a
very slow rate, requiring prolonged incubation times (24 h).
Additionally, during the trypanosomal NTR-mediated reduc-
tion of nifurtimox to the unsaturated open-chain nitrile, it is
implicit that nitroso and hydroxylamine intermediaries must
be formed (Fig. 3). However, peaks corresponding to these
derivatives were never detected, even when using substoichio-
metric concentrations ofNADH, indicating that these transient
intermediates undergo facile reduction and as such contribute
to the rapid conversion of nifurtimox to the unsaturated open-
chain nitrile.
The nifurtimox reduction product was unequivocally char-
acterized as an unsaturated open-chain nitrile using tandem
MS. Positive electrospray ionization (ESI)mass spectrometry of
the purified reduction product gave rise to two ions with m/z
values of 170 and 131, corresponding to molecular weights of
147 and 108 ([MNa]), respectively (Fig. 5A). These frag-
ments are the result of eliminative cleavage of the weak N-N
bond to give a truncated open-chain nitrile and a dehydrothi-
omorpholine (Fig. 5B). When the converse experiments were
FIGURE 2. Interaction of trypanosomal type I nitroreductases with nifur-
timox. A, schematic for nifurtimox (NFX) reduction by trypanosomal type I
nitroreductases (NTR), using NADH as electron donor. Reduced (red) and oxi-
dized (oxid) forms of nitrofuran are shown. B, type I nitroreductase activity
was assayed in the presence of nifurtimox (0–100 M), NADH (60 (Œ), 80 (f),
and 100 () M), and TcNTR (20 g). C, type I nitroreductase activity was
monitored under aerobic (F) and hypoxic (f) conditions using NADH (100
M), nifurtimox (0–300M), and TcNTR (20g). Type I nitroreductase activity
is expressed as mol of nifurtimox reduced min1 mg1 protein. The graph
shown is representative of three independent experiments. In B and C, the
data were evaluated by non-linear regression analysis using GraphPad Prism
5.D, oxygen consumption during nifurtimox reduction. Reactions containing
nifurtimox (100 M), NAD(P)H (100 M), and microsomes enriched for cyto-
chrome P450/cytochrome P450 reductase (0.1 g, curve a) or TcNTR (4 g,
curve b) were incubated at 27 °C, and the change in fluorescence was fol-
lowed. The amount of microsomal fraction and trypanosomal type I nitrore-
ductase usedwere equivalent in their rates of NAD(P)H oxidation. The rate of
NADPHoxidationby themicrosomal fractionwas21nmol ofNADPHoxidized
min1, whereas the rate of NADH oxidation by TcNTR was 22mmol of NADH
oxidized min1, as determined by parallel spectrophotometric assays. Con-
trols lacking substrate were also carried out (curve c), and an identical curve
was obtained when the enzyme was omitted. Additional controls to validate
this system are shown in supplemental Fig. S1. Results were normalized by
subtractionof thebackground signal in the absenceof the enzyme. All curves
are means from experiments performed in triplicate. When TbNTR was used
in place of TcNTR, similar enzyme kinetic and oxygen consumption profiles
were observed.
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performed using negative ESI-MS, a series of peaks predicted
for the unsaturated open-chain nitrile being the parental struc-
ture were detected (Fig. 5C). Themajor peak had am/z value of
227, which corresponds to the parental backbone lacking the
nitrile group, whereas a series of smaller fragments was also
observed whosem/z values are all consistent with the proposed
unsaturated open-chain nitrile (Fig. 5D).
Therefore, the predominant reaction catalyzed by both
TcNTR and TbNTR under aerobic or anaerobic conditions is a
two-step, two-electron reduction of nifurtimox that yields the
unsaturated open-chain nitrile derivative (Fig. 3).
Trypanocidal Activity of the Nifurtimox Reduction Products—
To evaluate whether the nifurtimox-derived unsaturated open-
chain nitrile displayed cytotoxicity, the reduction product was
purified and its growth inhibitory activity assessed against blood-
stream-form T. brucei andmammalian cells (Fig. 6). The concen-
tration of unsaturated open-chain nitrile that inhibited parasite
growth by 50% (IC50) was slightly higher than that determined for
nifurtimox itself (Fig. 6) (IC50 of 5.3  1.0 M for the reduction
product versus 2.9 0.3M for nifurtimox). In contrast,mamma-
lian cells were relatively resistant to nifurtimox but displayed
increased susceptibility to the TbNTR-derived metabolite. Com-
pare the IC50of 30.01.0Mfor theparent compoundwith5.4
1.1 M for the unsaturated open-chain nitrile. Therefore, the
reduced nifurtimox derivative no longer displays selectivity
towardT. brucei, suggesting that it is theNTR-mediatedreduction
step in the pathogen that is responsible for the difference in toxic-
ity between themammalian and parasite cells.When the cytotox-
icityof the saturatedopen-chainnitrilewasassessed,nosignificant
effectonparasiteormammaliancell growthwasobservedover the
screened range.
The importance of trypanosomal NTR-mediated reduction
of nifurtimox to its toxic product was clearly demonstrated
using T. brucei cells expressing elevated levels of TbNTR.
These parasites were10-fold more susceptible to nifurtimox
than controls (cells with elevated levels of TbNTR had an IC50
value of 0.34  0.02 M compared with 2.51  0.09 M
observed for controls), whereas they displayed similar levels of
sensitivity to the unsaturated open-chain nitrile (3.71  0.51
M for T. brucei overexpressing TbNTR compared with 3.65
0.16 M in controls). Together, these data show that the unsat-
urated open-chain nitrile metabolite derived following TcNTR
or TbNTR-mediated nifurtimox reduction contributes to tox-
icity of this nitrofuran and that it is the presence of a type I
nitroreductase in the parasite that is responsible for the selec-
tive toxicity of nifurtimox against these pathogens.
DISCUSSION
The mode of action and basis of selectivity of the anti-
trypanosomal compound nifurtimox has been an enigma since
its introduction as a therapy for Chagas disease. In this article
we provide evidence showing that trypanosomal type I nitrore-
ductases catalyze reduction of this prodrug to an unsaturated
open-chain nitrile derivative (Figs. 4 and 5) and that the prod-
uct, unlike the nitrofuran precursor, displays equivalent growth
inhibitory properties against parasite and mammalian cells
(Fig. 6). Together, these findings demonstrate that selective
toxicity of nifurtimox may be attributable to type I nitroreduc-
tase expression by trypanosomes and indicate that this prodrug
mediates a significant component of its anti-parasitic activity
by a mechanism other than induction of oxidative stress.
Activation of nitrofurans can occur by two routes, involving
the two-electron reduction of the compound, reactions medi-
ated by type I nitroreductases, or a one-electron pathway, as
catalyzed by type II enzymes. Bacteria express both activities,
but it is the type I system that underpins the selectivity of nitro-
furan antibiotics (39–41). Prokaryotes selected for resistance
to nitrofurazone invariably acquire mutations in their type I
FIGURE 3. Reduction of nitrofurans by type I nitroreductases. Type I nitroreductases reduce the conserved nitro group of nitrofurans to generate a
hydroxylamine via a nitroso intermediate. The hydroxylamine can bemetabolized further to form 1) a nitrenium ion, 2) the amine form, or 3) unsaturated and
then saturated open-chain nitriles (11–16).
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nitroreductase genes. Following activation, the precise antimi-
crobial action of these prodrugs is largely unknown, but it is
believed to rely on production of toxic intermediate metabo-
lites that ultimately triggerDNAdamage and cell death (12, 13).
In contrast, nitrofuran reduction in eukaryotic cells is generally
mediated by enzymes with a type II activity, leading to nitro
anion radical formation. In an aerobic environment, the radical
then undergoes futile cycling, resulting in regeneration of the
parental nitro-compound and production of reactive oxygen
species (11, 17, 19, 36). The latter may then induce a state of
oxidative stress in the target cell. Mammalian cells do express
enzymes that can mediate the two-electron reduction of
nitroaromatic compounds (42–44), butmany of these activities
are low in normal tissues and elevated in tumor cells, a differ-
ence that has been exploited in the development of anti-cancer
therapies (45). Whether such eukaryotic enzymes play a role in
nitrofuran metabolism has not been addressed.
The predominance of type II nitroreductases in eukaryotic
cells, coupled with observations that nifurtimox-treated
trypanosome extracts generated superoxide anions and nitro
anion radicals, supported the proposal that parasite killing
activity was mediated by the induction of oxidative stress. As a
consequence, the presence of trypanosomal type I enzymes and
their role in nitrofuran activation has been largely overlooked.
However, following the identification of the trypanosomal type
I nitroreductase and demonstration of its key role in nitroaro-
matic drug toxicity, the mechanism of nifurtimox action needs
to be re-evaluated (27). Against this backdrop, we overex-
pressed prostaglandin F2 synthase and two cytochrome P450
reductases, enzymes reported to interact with nifurtimox (29,
34) and demonstrated that elevation of their levels in blood-
stream-form T. brucei had no effect on toxicity (Fig. 1). In con-
trast, the central role of the NTR in this process was clearly
demonstrated, as parasites with elevated levels were hypersen-
sitive to nifurtimox (Fig. 1) in agreement with our previous
work (27, 32, 35). Additionally, in awhole-genome “loss of func-
tion” screen using nifurtimox against an induced T. brucei
RNAi library, the only hits generated targeted the TbNTR tran-
script (28). Therefore, NTR remains the only trypanosomal
enzyme with a confirmed role in nifurtimox activation within
the parasite.
The ability of the NTR to reduce nitroheterocyclic com-
pounds, including nifurtimox, under aerobic conditions indi-
cates that this enzyme is a type I nitroreductase. Our observa-
tion that nifurtimox metabolism was slightly more efficient
under anaerobic than aerobic conditions and the low level of
oxygen consumption (Fig. 2) are fully consistent with the activ-
ity reported for Escherichia coli oxygen-insensitive enzymes,
previously ascribed to protein impurities (11). The effect of
oxygen on activity may reflect that certain intermediaries gen-
erated by type I catalysis are prone to oxidation (46). Some
hydroxylamines can be oxidized when exposed to air. Alterna-
tively, the type I/type II dichotomy may be less absolute than
previously thought. In any case, it is clear that the predominant
mode of NTR action is via a two-electron reduction pathway.
Several different reaction products have been identified from
the type I-mediated reduction of nitrofurans, including amines
and open-chain nitriles (11, 15, 16). However, in many cases
these are reported to be biologically inactive. Instead, prodrug
toxicity is believed to occur via formation of protein and nucleic
acid adducts with reactive intermediates such as the hydroxyl-
amine or nitrenium ions (12, 13, 47). Here, we demonstrated
that the nitrile product generated from nifurtimox is toxic to
bloodstream-form trypanosomes, displaying an IC50 value
comparable with that of the parent compound (Fig. 6). Addi-
tionally, unlike nifurtimox itself, the metabolite also demon-
strated significant growth inhibitory activity against a cultured
mammalian cell line. For most nitrofurans, reduction to the
open-chain nitrile is reported to go to completion, with the
biologically inactive saturated form being the main end prod-
uct. For nifurtimox reduction this is not the case, and themajor
open-chain nitrile formed is in the unsaturated state. One
explanation for why other groups have not detected significant
quantities of the unsaturated open-chain nitrile is that products
were isolated after prolonged incubation (48 h) or were
FIGURE 4. Trypanosomal type I nitroreductase-mediated nifurtimox
reductiongeneratesanunsaturatedopen-chainnitrile.A, HPLC trace (
340 nM) of the reaction product obtained after complete reduction of nifurti-
mox by the trypanosomal type I nitroreductase TcNTR. TbNTR generates
exactly the same metabolic profile. B, mass spectrum of the single peak
obtained after HPLC. The m/z of 256 and 278 correspond to the nifurtimox-
derived metabolite H or Na, respectively. The calculated molecular
weight of 255 corresponds to anunsaturatedopen-chain nitrile form (see Fig.
3). C, absorption spectrum of the unsaturated open-chain nitrile product.
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derived from animals during pharmacological testing (15, 16),
whereas in our system, LC/MS analysis of the nifurtimox-de-
rived material was performed within 60 min of initiating the
reaction. However, even after 24 h, the unsaturated open-chain
nitrile product generated from nifurtimox was still the major
peak in traces, with only small amounts of the saturated form
detectable. This indicates that the unsaturated open-chain
nitrile derived from this trypanocidal prodrug is relatively sta-
ble, and this stability may explain why nifurtimox is an effective
anti-parasitic agent despite being a poor substrate for the
trypanosomal type I nitroreductases compared with other
nitroheterocyclic compounds (32, 35). As unsaturated open-
chain nitriles have rarely been observed following nitroreduc-
tion, their role in nitrofuran toxicity has been overlooked, and
the mechanism of action is unknown. The unsaturated open-
chain nitrile derived from nifurtimox has the potential to func-
tion as aMichael acceptor and could react non-specifically with
a range of cellular components. This may explain the pleiotro-
pic effects of nifurtimox on trypanosomes, where treatment has
been reported to inhibit various enzyme activities, modify thiol
levels, and cause DNA damage (21, 48–51).
We have now shown that nifurtimox reduction by a trypano-
somal type I nitroreductase leads to formation of a toxic prod-
uct. The precise mode of action of the resultant unsaturated
open-chain nitrile product remains to be determined, but given
that it is equally toxic to mammalian and parasite cells, it is
FIGURE 5. Tandemmass spectrometry of the open-chain nitrile. A, positive ESI tandemMS of the unsaturated open-chain nitrile ion described in Fig. 4 (P;
m/z of 278 corresponding to [MNa]) generated two fragments withm/z values of 170 and 131. B, structure of precursor unsaturated open-chain nitrile ion
(278) and fragment peaks after positive ESI. C, negative ESI tandemMS of them/z 254 [M-H] precursor ion generated several peaks.D, structure of precursor
and fragment peaks following negative ESI.
FIGURE6.Cytotoxicityof theunsaturatedopen-chainnitrile.Dose-depen-
dent response of bloodstream-form T. brucei (f) and mammalian THP-1 ()
cells to nifurtimox (NFX) (solid line) and its unsaturated open-chain nitrile
product (OCN) (dotted line). All curves are means from experiments per-
formed in quadruplicate. The insert contains the mean IC50 values S.D.
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plausible that the downstream targets are common to both host
and pathogen. If this is the case, then the basis of nifurtimox
selectivity is due to expression of the type I nitroreductase in the
parasite. Understanding how nifurtimox exerts its trypanocidal
effects may lead to the development of novel anti-parasitic
drugs that utilize the bioreductive activity of this enzyme.
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